Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR/MSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.

NCT07779694 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT07779694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07779694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR/MSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2029
Enrollment
51 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fasting, intermittent, locally advanced rectal carcinoma, pmmr/mss